External quality assessment for immunohistochemistry: experiences from NordiQC

References

• Borrisholt M, Nielsen S, Vyberg M (2013) Demonstration of CDX2 is highly antibody dependent. Appl. Immunohistochem. Mol. Morphol. 21: 64–72.
   PubMedGoogle Scholar
• Copete M, Garratt J, Gilks B, Pilavdzic D, Berendt R, Bigras G, Mitchell S, Lining LA, Cheung C, Torlakovic EE (2011) Inappropriate calibration and optimisation of pan-keratin (pan-CK) and low molecular weight keratin (LMWC K) immunohistochemistry tests: Canadian Immunohistochemistry Quality Control (CIQC) experience. J. Clin. Pathol. 64: 220–225.
   PubMed Web of Science ®Google Scholar
• Engel KB, Moore HM (2011) Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue Arch. Pathol. Lab. Med. 135: 537–543.
   PubMed Web of Science ®Google Scholar
• Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG (2007) Recommendations for improved standardization of immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 15: 124–133.
   PubMedGoogle Scholar
• Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch. Pathol. Lab. Med. 134: 48–72.
   PubMed Web of Science ®Google Scholar
• Howat WJ, Lewis A, Jones P, Kampf C, Pontén F, van der Loos CM, Gray N, Womack C, Warford A (2014) Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a consortium of academic and pharmaceutical based histopathology researchers. Methods. 4 doi: 10.1016/j.ymeth.2014.01.018. [Epub ahead of print].
   Google Scholar
• NordiQC (2011) http://www.nordiqc.org/Run-31-G1/Assessment/assessment-31-CGA.htm
   Google Scholar
• NordiQC (2013a) http://www.nordiqc.org/Run-37-B15-H3/Assessment/assessment-37-CD45.htm
   Google Scholar
• NordiQC (2013b) http://www.nordiqc.org/Run-37-B15-H3/Assessment/assessment-37-CEA.htm
   Google Scholar
• NordiQC (2013c) http://www.nordiqc.org/Run-38/Assessment/assessment-38-CK-LMW.htm
   Google Scholar
• NordiQC (2014) http://www.nordiqc.org/Run-41/Assessment/Run41_BSAP.pdf
   Google Scholar
• O’Hurley G, Sjöstedt E, Rahman A, Li B, Kampf C, Pontén F, Gallagher WM, Lindskog C (2014) Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol. Oncol. 8: 783–798.
   PubMed Web of Science ®Google Scholar
• Taylor CR (2000) The total test approach to standardization of immunohistochemistry. Arch. Pathol. Lab. Med. 124: 945–951.
   PubMed Web of Science ®Google Scholar
• Torlakovic EE, Francis G, Garratt J, Gilks B, Hyjek E, Ibrahim M, Miller R, Nielsen S, Petcu EB, Swanson PE, Taylor CR, Vyberg M (2014) Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel. Appl. Immunohistochem. Mol. Morphol. 22: 241–252.
   PubMedGoogle Scholar
• Vyberg M, Torlakovic E, Seidal T, Risberg B, Helin H, Nielsen S (2005) Nordic immunohistochemical quality control Croat. Med. J. 46: 368–371.
   Google Scholar
• Wasielewski Rv, Hasselmann S, Rüschoff J, Fisseler-Eckhoff A, Kreipe H (2008) Proficiency testing of immunohistochemical biomarker assays in breast cancer. Virchows Arch. 453: 537–543.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch. Pathol. Lab. Med. 131: 18–43.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2014) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch. Pathol. Lab. Med. 138: 241–256.
   PubMed Web of Science ®Google Scholar
• Yaziji H, Taylor CR, Goldstein NS, Dabbs DJ, Hammond EH, Hewlett B, Floyd AD, Barry TS, Martin AW, Badve S, Baehner F, Cartun RW, Eisen RN, Swanson PE, Hewitt SM, Vyberg M, Hicks DG (2008) Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 16: 513–520.
   PubMedGoogle Scholar